###begin article-title 0
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 30 35 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 11 12 11 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 123 128 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
DSB, the 3-O-(3',3'dimethylsuccinyl) derivative of betulinic acid, blocks the last step of protease-mediated processing of HIV-1 Gag precursor (Pr55Gag), which leads to immature, noninfectious virions. When administered to Pr55Gag-expressing insect cells (Sf9), DSB inhibits the assembly and budding of membrane-enveloped virus-like particles (VLP). In order to explore the possibility that viral factors could modulate the susceptibility to DSB of the VLP assembly process, several viral proteins were coexpressed individually with Pr55Gag in DSB-treated cells, and VLP yields assayed in the extracellular medium.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 18 20 18 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 430 433 430 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">108</sup>
###xml 434 437 434 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">114</sup>
###xml 438 441 438 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">133</sup>
###xml 442 446 442 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">139 </sup>
###xml 541 544 541 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
Wild-type Vif (Vifwt) restored the VLP production in DSB-treated cells to levels observed in control, untreated cells. DSB-counteracting effect was also observed with Vif mutants defective in encapsidation into VLP, suggesting that packaging and anti-DSB effect were separate functions in Vif. The anti-DSB effect was abolished for VifC133S and VifS116V, two mutants which lacked the zinc binding domain (ZBD) formed by the four H108C114C133H139 coordinates with a Zn atom. Electron microscopic analysis of cells coexpressing Pr55Gag and Vifwt showed that a large proportion of VLP budded into cytoplasmic vesicles and were released from Sf9 cells by exocytosis. However, in the presence of mutant VifC133S or VifS116V, most of the VLP assembled and budded at the plasma membrane, as in control cells expressing Pr55Gag alone.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 188 190 188 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 16 21 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The function of HIV-1 Vif protein which negated the DSB inhibition of VLP assembly was independent of its packaging capability, but depended on the integrity of ZBD. In the presence of Vifwt, but not with ZBD mutants VifC133S and VifS116V, VLP were redirected to a vesicular compartment and egressed via the exocytic pathway.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 6 7 6 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 105 106 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 107 108 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 232 233 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 234 235 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 236 237 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 512 513 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 584 585 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 586 587 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 588 589 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 590 592 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 710 711 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 712 713 703 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 714 715 705 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 716 718 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 865 874 856 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 887 889 878 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 954 962 945 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 963 965 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 155 160 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 689 694 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The 3-O-(3',3'-dimethylsuccinyl)-betulinic acid (or YK-FH312 [1], or PA-457 [2], or Bevirimattrade mark [3,4]), has been used as an antiviral which blocks HIV-1 replication via its inhibitory activity on Gag polyprotein maturation [2,5-8]. DSB differs from conventional protease (PR) inhibitors in that it does not bind to PR, but interferes with the PR-mediated Gag processing. The ultimate cleavage of the C-terminal capsid domain CAp25 into CAp24 + SP1 is required for production of fully infectious virions [9]. DSB blocks this step, and decreases or abolishes virus infectivity [2,4,6,10]. Several lines of evidence indicate that the CA-SP1 junction is the preferred target of DSB in HIV-1 Gag precursor [3,4,8,11]. Although there is no available structural data on DSB-Gag complex which could explain its inhibitory activity at the molecular level, data from in vitro experiments [12], as well as the encapsidation of DSB in equimolar ratio to Gag in vivo [13], suggested that the mechanism of inhibitory activity of DSB results from the direct binding of DSB to the Gag polyprotein, or/and to a transient Gag structural intermediate which occurs during virus assembly.
###end p 9
###begin p 10
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 633 636 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">SIV</sup>
###xml 856 857 856 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1062 1064 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1269 1271 1269 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 97 102 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 267 272 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1100 1103 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The latter observation incited us to study the possible effect of DSB on assembly of recombinant HIV-1 Gag precursor (Pr55Gag) expressed in heterologous, eukaryotic system. We observed a dose-dependent negative effect of DSB on the process of assembly and release of HIV-1 VLP from recombinant baculovirus AcMNPV-Pr55Gag-infected cells [14]. This effect was not due to a block in Gag synthesis, and was independent of the N-myristoylation of Pr55Gag and its plasma membrane addressing. It did not depend on the presence of the p6 domain at the C-terminus of Gag. The same effect was observed with the Gag precursor of SIVmac (Pr57GagSIV), although at significantly higher DSB concentrations, suggesting that the DSB inhibitory activity on Gag assembly was not as strictly sequence-dependent as the negative effect on Gag processing at the CA-SP1 junction [8]. In addition, we found a lower stability of delipidated cores assembled in the presence of DSB, compared to control cores, suggesting a weakening of Gag-Gag interaction occurring in the presence of DSB [14]. Using Gag mutants and a chimeric HIV-MuLV Gag precursor, we mapped the DSB-responsive domain in terms of Gag assembly to the hinge region overlapping the C-terminal end of the CAp24 and the SP1 domain [14].
###end p 10
###begin p 11
###xml 385 387 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 401 402 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 435 437 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 626 628 624 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 638 640 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 681 683 678 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 712 714 709 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9 </sup>
###xml 219 224 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The DSB concentration at which we observed an inhibitory activity on Gag assembly in insect cells (IC50 ~8-10 muM) was apparently disproportionate compared to the usual doses required for blocking the CAp25 cleavage in HIV-1-infected mammalian cells. However, a wide range of IC-50 values have been reported for the DSB inhibition of virus maturation, varying from nanomolar (0.35 nM [15] and 7.8 nM [2]) to micromolar values (10 muM [12]), depending on the different assays used. In addition, in Pr55Gag-expressing Sf9 cells, the bulk of Gag protein molecules synthesized at 48 h pi has been evaluated to be as high as 5 x 108 per cell [16]. The addition of DSB at 10 mug/ml to 106 cells corresponded to 12 x 109 DSB molecules per cell, i.e. a DSB to Gag stoichiometric ratio of 24: 1 at this DSB concentration. A 24-fold excess of DSB over Gag was therefore compatible with a mechanism of Gag assembly inhibition due to a stoichiometric interaction between the drug and its protein target.
###end p 11
###begin p 12
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 284 285 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 654 655 654 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1007 1009 1007 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1141 1143 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1144 1146 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1281 1283 1281 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1302 1304 1302 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 175 180 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 190 195 <span type="species:ncbi:9606">human</span>
###xml 1289 1294 <span type="species:ncbi:9606">human</span>
Whatever the molecular mechanism, our observation raised the question of the difference between Pr55Gag-expressing Sf9 cells, in which DSB inhibited VLP assembly [14], versus HIV-1-infected human cells, in which DSB was found to block the CA-SP1 (CAp25) to CAp24 maturation cleavage [3,4,8,11], and to have limited effects on virus assembly [1]. In our experimental model of baculovirus-infected cells [14], assembly of Pr55Gag was analyzed in a context devoid of PR and of glycoproteins (Gp) SUgp120 and TMgp41, three viral components which have been identified as directly or indirectly involved in the antiviral effects of betulinic acid derivatives [8,17,18]. In the aim to reconcile the different antiviral activities of DSB, we explored cellular and viral determinants of the DSB response, and their possible role in modulating the degree of susceptibility to DSB of the VLP assembly process. Among the viral candidates, we analyzed EnvGp160, the precursor to the envelope glycoproteins (reviewed in [19]), and two inner core components, the Vpr and Vif proteins. Vpr is packaged into the virion in substoichiometric amounts with Gag [20-23], and Vif, which is also coencapsidated with Gag, has been found to exert a control on proteolytic processing of Gag in insect cells [24] and human cells [25].
###end p 12
###begin p 13
###xml 56 58 56 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 528 530 528 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
We found that coexpression of wild-type Vif protein (Vifwt) with Pr55Gag restored the VLP assembly in DSB-treated Sf9 cells at levels observed in the absence of the drug, suggesting an antagonistic effect of Vif towards DSB. Data obtained with Vif mutants indicated that the anti-DSB function of Vif required the integrity of the zinc binding domain (ZBD) recently identified in the Vif protein [26-28], but was independent of the Vif packaging function. Electron microscopic analysis showed that coexpression of Pr55Gag and Vifwt, in the presence or absence of DSB, resulted in a major change in the VLP egress pathway: the majority of VLP budded in intracytoplasmic vesicles and were released by exocytosis, instead of budding at the plasma membrane as in cells expressing Pr55Gag alone. With ZBD mutants of Vif however, the VLP budding pathway was similar to that observed in cells expressing Pr55Gag alone. Our data suggested that the anti-DSB effect of Vif, a novel function associated with its ZBD, was the indirect consequence of its effect on the cellular pathway of VLP assembly and budding.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
Antiviral effects of DSB and cellular context
###end title 15
###begin p 16
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 138 143 138 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 288 291 288 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gag</italic>
###xml 293 299 293 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gagpol</italic>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">rev </italic>
###xml 309 313 309 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">env </italic>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 248 253 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We first compared the effect of DSB on VLP assembly and release in our reference model of AcMNPV-Pr55Gag-infected Sf9 cells [14] and in a trans-packaging mammalian cell line. 5BD.1 cells derive from CMT3-COS cells by integration of a discontinuous HIV-1 progenome, and stably express the gag, gagpol, rev and env gene products but no Nef protein. 5BD.1 cells also express Vif protein in significant amounts [29,30]. 5BD.1 and Sf9 cells represented a similar situation in terms of VLP content, as both cell types produced VLP devoid of viral genomic RNA. DSB was added to monolayers of 5BD.1 cells at increasing concentrations for 30 h, and whole cell lysates and VLP recovered from culture medium were analyzed for Gag protein content at the end of this time period.
###end p 16
###begin p 17
###xml 132 135 132 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1Ai</xref>
###xml 140 143 140 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1Bi</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 389 393 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1Aii</xref>
###xml 409 411 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 571 575 569 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1Bii</xref>
###xml 808 812 806 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1Bii</xref>
###xml 1091 1096 1089 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1Biii</xref>
###xml 1134 1135 1132 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1136 1137 1134 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1138 1139 1136 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1140 1142 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
The intracellular Gag content was found to remain constant throughout the period of DSB treatment in both Sf9 and 5BD.1 cells (Fig. 1Ai and 1Bi), which confirmed that DSB had no significant effect on the level of Gag protein synthesis [14]. However, a drastic decrease in the yields of extracellular VLP was observed at DSB doses superior to 4 mug/ml in Pr55Gag-expressing Sf9 cells (Fig. 1Aii; and refer to [14]). By contrast, only a moderate decrease in VLP production (20-30%) was detected for DSB-treated 5BD.1 cells at high DSB concentrations (12 to 16 mug/ml; Fig. 1Bii). Protein analysis of VLP showed that their Gag protein content mainly consisted of Pr55Gag and CAp24 proteins, with other minor species migrating at the expected position for intermediate cleavage products, e.g. Pr47 to Pr41 (Fig. 1Bii). Prolonged exposure of autoradiograms of immunoblots reacted with radiolabelled secondary antibody revealed a discrete alteration of the Gag processing at high DSB concentrations: there was a progressive increase in the amount of uncleaved CAp25 versus the CAp24 species (Fig. 1Biii), as expected from previous studies [3,4,8,11].
###end p 17
###begin p 18
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of DSB on HIV-1 VLP production by (A) insect cells and (B) mammalian cells</bold>
###xml 84 87 84 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A)</bold>
###xml 499 502 499 502 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(i)</bold>
###xml 691 695 691 695 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(ii)</bold>
###xml 717 718 717 718 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 906 909 906 909 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(i)</bold>
###xml 916 920 916 920 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(ii)</bold>
###xml 927 932 927 932 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(iii)</bold>
###xml 957 959 957 959 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ii</bold>
###xml 1024 1026 1024 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1067 1070 1067 1070 <bold xmlns:xlink="http://www.w3.org/1999/xlink">iii</bold>
###xml 18 23 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 478 484 <span type="species:ncbi:9986">rabbit</span>
Effects of DSB on HIV-1 VLP production by (A) insect cells and (B) mammalian cells. (A), Sf9 cells infected with AcMNPV-Pr55Gag were treated with increasing concentrations of DSB in DMSO-aliquots for 30h at 18h pi, as indicated on top of the panels. Cells were harvested at 48 h pi, and whole cell lysates (WCL) and extracellular VLP recovered from the culture medium were analyzed by SDS-PAGE and immunoblotting using anti-Gag polyclonal antibody and phosphatase-labelled anti-rabbit IgG antibody. (i), WCL. (*), Asterisk marks posttranslationally modified Gag precursor (ubiquitinated and/or phosphorylated). This Gag species was not included in the quantification of Pr55Gag polyprotein. (ii), Extracellular VLP. (B), 5BD.1 packaging cells were treated with increasing DSB concentrations in DMSO for 30 h, as indicated on top of the panels, and cells and VLP collected separately and analyzed as above. (i), WCL; (ii), VLP. (iii), Same experiment as in (ii), except for the immunoblot analysis, which was performed using 35S-labelled secondary antibody. Shown in (iii) is an autoradiogram of the blot. Molecular markers (m) were electrophoresed on the left side of the gels, and their molecular masses are indicated in kiloDaltons (kDa).
###end p 18
###begin p 19
###xml 249 254 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
VLP assembly and release were therefore less sensitive to DSB inhibitor in 5BD.1 cells compared to Gag-expressing Sf9 cells. This suggested that the DSB sensitivity of the VLP assembly pathway might be modulated by the cellular context in which the HIV-1 Gag precursor was expressed, or/and by viral proteins present in 5BD.1 cells and absent from Sf9 cells. The following experiments were designed to address this issue, and to determine which factor(s) possibly interfered with DSB inhibitory activity and accounted for the difference in DSB response between Sf9 and 5BD.1 cells, as well as other mammalian cells.
###end p 19
###begin title 20
Absence of detectable effect of EnvGp160 or Vpr on the DSB inhibition of VLP assembly in Sf9 cells
###end title 20
###begin p 21
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 92 97 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 169 181 <span type="species:ncbi:9606">participants</span>
The best candidates to act as viral modulators of the Gag assembly response to DSB were the HIV-1 proteins coencapsidated with Gag, in particular those which are active participants in the virus assembly pathway (reviewed in [19,31]). This was the case for the envelope glycoprotein Gp160, which has been shown to interact with the MA protein via the cytoplasmic tail of its TMgp41 domain [32-36], as well as for auxiliary viral proteins Nef, Vpr and Vif.
###end p 21
###begin p 22
###xml 582 587 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In order to test this possibility, Sf9 were coinfected with AcMNPV-Pr55Gag and AcMNPV-Gp160, and subjected to increasing doses of DSB for 30 h, at 18 h pi. Culture medium samples were collected at 48 h pi and assayed for production of extracellular VLP. Results were compared with VLP yields from Sf9 cells infected with AcMNPV-Pr55Gag alone and treated in parallel with DSB at the same doses. No significant difference in the DSB effect on VLP assembly was detectable with or without coexpression of EnvGp160 (data not shown). This excluded the direct or indirect participation of HIV-1 envelope glycoproteins in the level of susceptibility to DSB of assembly and extracellular release of VLP by Sf9 cells.
###end p 22
###begin p 23
###xml 67 77 67 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bona fide </italic>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 316 320 316 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1Bii</xref>
Nef in its processed form, called Nef core, has been shown to be a bona fide component of the virion inner core [37-40]. In 5BD.1 cells, which do not express Nef but express Vif [29,30], we observed a significantly lesser inhibitory effect of DSB on VLP assembly, compared to Gag-expressing Sf9 cells (refer to Fig. 1Bii). Considering that Nef protein was absent from both Sf9 and 5BD.1 cells, the difference in DSB response between these two cell types apparently excluded Nef as a possible modulator of the DSB sensitivity of VLP assembly.
###end p 23
###begin p 24
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 548 549 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Vpr is coencapsidated with Gag via interaction of the N-terminal alpha-helical domain encompassing residues 17-33 in Vpr [41-44] with the LXXLFG motif in the p6 domain of Gag [21,22,45-48]. In Sf9 coinfected with AcMNPV-Pr55Gag and AcMNPV-Vpr, the same DSB sensitivity of VLP assembly was observed as in cells solely expressing AcMNPV-Pr55Gag: both Pr55Gag and Vpr protein signals decreased in parallel and in DSB dose-dependent manner in the extracellular medium of DSB-treated cells, although their intracellular content remained unchanged (Fig. 2). This implied that Vpr did not significantly interfere with the inhibitory effect of DSB on Gag assembly.
###end p 24
###begin p 25
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Absence of counteracting effect of Vpr on DSB inhibition of HIV-1 VLP assembly and release</bold>
###xml 645 648 645 648 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A)</bold>
###xml 655 658 655 658 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B)</bold>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 538 543 <span type="species:ncbi:10090">mouse</span>
###xml 579 585 <span type="species:ncbi:9986">rabbit</span>
###xml 624 630 <span type="species:ncbi:9986">rabbit</span>
Absence of counteracting effect of Vpr on DSB inhibition of HIV-1 VLP assembly and release. Sf9 cells were coinfected with two baculoviruses at equal MOI each (5 PFU/cell), one expressing Pr55Gag, the other expressing His-tagged Vpr. Cells were treated with increasing concentrations of DSB in DMSO aliquots for 30 h at 18 h pi, as indicated on top of the panels. Cells were harvested at 48 h pi, and whole cell lysates (WCL) and extracellular VLP analyzed by SDS-PAGE and immunoblotting, using anti-His mAb and phosphatase-labelled anti-mouse IgG antibody, followed by anti-Gag rabbit antibody and peroxidase-labelled anti-rabbit IgG antibody. (A), VLP. (B), WCL. Note the occurrence of Vpr dimer (Vprx2; 30 kDa), stained in blue with the phosphatase reaction. (m), prestained molecular mass markers; (kDa), kiloDaltons.
###end p 25
###begin title 26
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 54 59 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Antagonistic effect of Vifwt on the DSB inhibition of HIV-1 VLP assembly
###end title 26
###begin p 27
###xml 58 67 58 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 71 79 71 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 355 358 355 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 612 615 611 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 715 720 714 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b, c</xref>
###xml 864 869 862 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b, c</xref>
###xml 983 985 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 262 267 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif protein has been shown to interact with Pr55Gag in vitro and in vivo [49,50], to control the viral PR-mediated processing of Gag in mammalian and insect cells [24,25,51], and to be coencapsidated with Gag at a level of 70-100 copies of Vif protein per HIV-1 virion or VLP [24,25,50,52-57]. Sf9 cells coinfected with AcMNPV-Pr55Gag and AcMNPV-Vifwt showed a pattern of DSB effect different from that observed in cells expressing Pr55Gag alone: there was no significant decrease in the VLP yields from DSB-treated Sf9 cells, up to drug concentrations as high as 20 mug/ml, implying that expression of Vifwt protein negated the DSB inhibition of VLP assembly process in Pr55Gag-expressing insect cells (Fig. 3b, c). Of note, the Vif content of VLP progressively decreased in a DSB-dependent manner (25-30% less than in control sample at 20 mug/ml DSB; Fig. 3b, c), although the intracellular content of Vif and Pr55Gag remained stable up to high DSB doses (16-20 mug/ml; Fig. 3a). This suggested a direct or indirect interference of Vif with DSB in virus assembly, resulting in the abrogation of the DSB negative effect on this process.
###end p 27
###begin p 28
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Influence of Vif on the DSB susceptibility of HIV-1 VLP assembly in Sf9 cells</bold>
###xml 333 334 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 656 659 656 659 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 848 851 848 851 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 974 977 974 977 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 1288 1290 1288 1290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1258 1264 <span type="species:ncbi:9986">rabbit</span>
###xml 1316 1322 <span type="species:ncbi:9986">rabbit</span>
Influence of Vif on the DSB susceptibility of HIV-1 VLP assembly in Sf9 cells. Sf9 cells were coinfected with equal MOI (5 PFU/cell) of two baculoviruses expressing Pr55Gag and Vif, respectively. Cells were treated with increasing concentrations of DSB in DMSO for 30 h at 18 h pi, as indicated on top of panels (a) and (b), and the x-axis of panel (c). Cells were harvested at 48 h pi, and whole cell lysates (WCL) and extracellular VLP analyzed by SDS-PAGE and immunoblotting. Blots were reacted with anti-Vif primary antibody and secondary phosphatase-labelled antibody, followed by anti-Gag primary antibody and secondary peroxidase-labelled antibody. (a), WCL. (*), Asterisk marks posttranslationally modified Gag precursor (ubiquitinated and/or phosphorylated). This Gag species was not included in the quantification of Pr55Gag polyprotein. (b), VLP. Molecular mass of prestained markers (m) are indicated in kiloDaltons (kDa) on the left side of panels (a) and (b). (c), Quantification of Gag and Vif proteins in WCL (IC-Gag, intracellular Gag; IC-Vif, intracellular Vif) and extracellular VLP, using SDS-PAGE and radio-immunoblotting. Gag and Vif protein contents were quantified by autoradiography of immunoblots reacted with anti-Gag and anti-Vif rabbit primary antibodies and 35S-labelled secondary anti-rabbit IgG antibody. After autoradiography of the blots, bands of Pr55Gag and Vif proteins were excised and their radioactive content determined by liquid scintillation spectrometry. Results were expressed as percentage of control, untreated samples, which was attributed the 100% value. Mean of three separate experiments +/- standard deviation.
###end p 28
###begin title 29
Anti-DSB activity of packaging-defective mutants of Vif
###end title 29
###begin p 30
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 345 348 345 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 351 353 351 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">76</sup>
###xml 358 361 358 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">80 </sup>
###xml 364 366 364 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">76</sup>
###xml 371 373 371 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">80</sup>
###xml 379 382 379 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 385 387 385 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">89</sup>
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">90</sup>
###xml 393 396 393 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">94 </sup>
###xml 399 401 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">89</sup>
###xml 403 405 403 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">90</sup>
###xml 407 409 407 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">94</sup>
###xml 429 432 429 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 435 438 435 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 440 443 440 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 468 471 468 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 510 513 506 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 515 518 511 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 663 666 659 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 672 675 668 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 684 687 680 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 756 758 752 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 811 814 807 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 825 827 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 980 981 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1035 1037 1027 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1087 1090 1079 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 1091 1093 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
In a previous study, we have constructed and characterized Vif mutants which differed from Vifwt in their efficiency of copackaging with Pr55Gag into VLP produced by recombinant baculovirus-coinfected cells [50]. The two discrete regions involved in this function spanned residues 76-80 and 89-94, respectively (Fig. 4). Substitution mutants VifsubA (76EKEWH80 to 76DINQN80), VifsubB (89WR90-Y94 to 89FE90-F94), double mutant VifsubC (subA+subB), and triple mutant VifsubCDelta170 carrying the double mutation subA+subB and a deletion of the C-terminal twenty-three residues, were found to be defective to various degrees in the encapsidation of Vif into VLP: VifsubA, VifsubB and VifsubC were partially defective in Vif packaging (40-50% the levels of Vifwt), whereas this function was totally abolished in VifsubCDelta170 [50]. On the opposite, VifKRA8, a full-length Vif mutant which had eight basic residues in the C-terminal domain replaced by neutral alanine residues (Fig. 4) and lacked the plasma membrane addressing function [54], was packaged into VLP at levels higher than Vifwt [50], suggesting that plasma membrane localization and encapsidation into VLP were distinct functions in Vif.
###end p 30
###begin p 31
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genotype and expression of recombinant Vif mutants in Sf9 cells</bold>
###xml 65 68 65 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A)</bold>
###xml 326 329 326 329 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B)</bold>
###xml 888 891 888 891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 1082 1085 1082 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 130 135 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Genotype and expression of recombinant Vif mutants in Sf9 cells. (A), Sequence alignment of the central and C-terminal domains of HIV-1 Vif proteins, WT and mutants. The zinc binding domain (ZBD) and its three constitutive loops are boxed: loops 1 and 3 are indicated as dark grey boxes, central loop 2 as a lighter grey box. (B), Cellular expression of recombinant Vif proteins, wild-type and mutants, in baculovirus-infected Sf9 cells. Sf9 cells were infected with baculoviruses (MOI 5) expressing different forms of Vif, as indicated on top of the panel, and harvested at 48 h pi. Whole cell lysates were analyzed by SDS-PAGE and immunoblotting, using anti-Vif primary antibody and secondary peroxidase-labelled antibody. The full-length ZBD mutants VifC133S and Vif116V show an aberrant electrophoretic mobility, as they migrate with a higher apparent molecular weight compared to Vifwt (23 kDa), and a higher sensitivity to proteolysis, as evidenced by the discrete bands of lower molecular weight breakdown products. Note the propensity of the Vif protein of triple mutant VifsubCDelta170 (20 kDa) to dimerize (Vifx2; 40 kDa).
###end p 31
###begin p 32
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 306 309 306 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 324 329 324 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b, c</xref>
###xml 386 389 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 552 557 552 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b, c</xref>
###xml 619 622 619 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 629 632 629 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 693 696 693 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 702 705 702 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 715 718 715 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 822 825 818 821 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
We then tested the anti-DSB activity of Vif mutants with different encapsidation phenotypes. With VifsubC, the production of extracellular VLP remained virtually unchanged throughout the DSB concentration range, with less than 15% decrease in VLP production at high DSB doses (Fig. 5). As observed with Vifwt (refer to Fig. 3b, c), there was a DSB-dependent, progressive decrease of VifsubC mutant protein content in VLP, relative to the Pr55Gag content, with 20-30% lesser Vif protein incorporated at high DSB doses, compared to control samples (Fig. 5b, c, samples 16-20). A similar DSB resistance pattern as with Vifwt and VifsubC was observed with the other packaging-defective mutants VifsubA, VifsubB, and VifsubCDelta170 (not shown). Likewise, the packaging-efficient mutant VifKRA8 showed the same phenotype as Vifwt and the packaging-defecting mutants in terms of anti-DSB activity (not shown). These results suggested that the DSB-counteracting function of Vif was independent from the packaging function of Vif.
###end p 32
###begin p 33
###xml 55 58 55 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 0 103 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Counteracting effect of packaging-defective mutant Vif <italic>sub</italic>C on the DSB inhibition of HIV-1 VLP assembly</bold>
###xml 289 292 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 435 436 435 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 740 743 740 743 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 750 753 750 753 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 858 861 858 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 929 932 929 932 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 1085 1087 1085 1087 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1063 1069 <span type="species:ncbi:9986">rabbit</span>
###xml 1113 1119 <span type="species:ncbi:9986">rabbit</span>
Counteracting effect of packaging-defective mutant Vif subC on the DSB inhibition of HIV-1 VLP assembly. Sf9 cells were coinfected with two baculoviruses at equal MOI of each (5 PFU/cell), one expressing Pr55Gag, the other expressing the double substitution, packaging-defective mutant VifsubC. Cells were treated with increasing concentrations of DSB in DMSO for 30 h at 18 h pi, as indicated on top of panels (a) and (b), and on the x-axis of panel (c). Cells were harvested at 48 h pi, and whole cell lysates (WCL) and extracellular VLP analyzed by SDS-PAGE and immunoblotting, using anti-Vif primary antibody and secondary phosphatase-labelled antibody, followed by anti-Gag primary antibody and secondary peroxidase-labelled antibody. (a), WCL; (b), VLP. Note the low level of Vif protein in VLP, consistent with the packaging-defective phenotype of VifsubC [50]. (m), prestained molecular mass markers; (kDa), kiloDaltons. (c), Quantification of Pr55Gag and Vif protein content of VLP, performed by autoradiography of immunoblots with anti-Gag and anti-Vif rabbit antibodies and 35S-labelled secondary anti-rabbit IgG antibody, as described in the legend to Fig. 3 (c). Results were expressed as percentage of control, untreated samples, which was attributed the 100% value. Mean of three separate experiments +/- standard deviation.
###end p 33
###begin title 34
Involvement of the zinc-binding domain of Vif in its anti-DSB function
###end title 34
###begin p 35
###xml 165 168 165 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">108</sup>
###xml 171 174 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">114</sup>
###xml 177 181 177 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">133 </sup>
###xml 186 190 186 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">139 </sup>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 936 938 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1077 1079 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1340 1342 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 625 630 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1050 1055 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1060 1063 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
A conserved region of the Vif protein, within residues 108 to 140, has been recently characterized as a non-canonical zinc-coordinating structure, generated by the H108, C114, C133 and H139 coordinates (HCCH) with a Zn atom [27,28]. This zinc-binding domain (ZBD) has been identified as the interacting region with the Cullin5 (Cul5) E3-ubiquitin ligase [28]. It has been shown that Vif recruits cellular proteins ElonginB/ElonginC and Cul5 via its BC-box and ZBD domain, respectively, and the resulting E3-ubiquitin ligase complex polyubiquitinates APOBEC3G and redirects it to the proteasome [27,28,58-60]. Position 116 in HIV-1 Vif belongs to the ZBD domain, and more precisely to the N-terminal portion of loop 2, the large loop defined by the two cysteine residues at positions 114 and 133 [26,28] (Fig. 4A). It has been recently found that replacement of Ser by Ala at position 116 in Vif did not change the Vif-Cul5 interaction [28]. This result was not totally surprising since position 116 can be occupied by serine, threonine or alanine in HIV-1 and SIV-CPZ strains [61], all residues characterized by short, hydrophilic or hydrophobic, side chains. However, these authors observed that deletion of Ser-116 abolished the Vif-Cul5 interaction, implying that the amino acid residue spacing in loop 2 was critical for Vif functions [28].
###end p 35
###begin p 36
###xml 400 403 400 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 409 412 409 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6Bi</xref>
###xml 631 634 631 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6Bi</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
Taking the latter observation into account, we substituted the serine residue to a valine at position 116. We assumed that the bulky side chain of valine would introduce local disorganization in the 3D structure of the ZBD domain, as did the S116 deletion, and would be detrimental to the anti-DSB effect of Vif. We found that the VifS116V mutant was coencapsidated with Gag at the same levels as Vifwt (Fig. 6Bi, lane 0). However, the assembly and extracellular release of VLP from Sf9 cells coexpressing Pr55Gag and VifS116V showed the same degree of DSB susceptibility as the one observed when Pr55Gag was expressed alone (Fig. 6Bi, and Fig. 6C). Thus, the lack of antagonistic effect against DSB of the packageable mutant VifS116V confirmed that anti-DSB function and packaging into VLP were separate functions in the Vif protein.
###end p 36
###begin p 37
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Absence of anti-DSB effect of zinc-binding domain mutants of Vif</bold>
###xml 204 219 204 219 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A and B, (i)) </bold>
###xml 231 246 231 246 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A and B, (ii))</bold>
###xml 389 390 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 694 697 694 697 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A)</bold>
###xml 704 707 704 707 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B)</bold>
###xml 774 777 774 777 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C)</bold>
###xml 962 964 962 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 990 996 <span type="species:ncbi:9986">rabbit</span>
Absence of anti-DSB effect of zinc-binding domain mutants of Vif. Sf9 cells were coinfected with two baculoviruses at equal MOI of each (5 PFU/cell), one expressing Pr55Gag, the other expressing VifS116V (A and B, (i)) or VifC133S (A and B, (ii)). Cells were treated with increasing concentrations of DSB in DMSO for 30 h at 18 h pi, as indicated on top of panels (i) and (ii), and on the x-axis of panel (C). Cells were harvested at 48 h pi, and whole cell lysates (WCL) and extracellular VLP analyzed by SDS-PAGE and immunoblotting, using anti-Vif primary antibody and secondary peroxidase-labelled antibody, followed by anti-Gag primary antibody and phosphatase-labelled secondary antibody. (A), WCL; (B), VLP. (m), prestained molecular mass markers; (kDa), kiloDaltons. (C), Quantification of VLP produced by DSB-treated Sf9 cells coexpressing Pr55Gag and Vif mutants was performed using SDS-PAGE and autoradiography of immunoblots reacted with anti-Gag and 35S-labelled secondary anti-rabbit IgG antibody, as described in the legends to Fig. 3(c) and 5(c). Results were expressed as percentage of control, untreated samples, which was attributed the 100% value. Mean of three separate experiments +/- standard deviation.
###end p 37
###begin p 38
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 587 590 587 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 596 600 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6Bii</xref>
###xml 889 893 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6Bii</xref>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
To further analyze the role of the ZBD structure in the Vif anti-DSB activity, we constructed another mutant of recombinant Vif protein. Cysteine at position 133 in Vif is a residue essential for virus infectivity [62,63], for Zn coordinate formation and ZBD-associated functions in Vif [27,28]. We therefore generated mutation C133S in recombinant Vif, and tested mutant VifC133S in co-expression with Pr55Gag in control or DSB-treated Sf9 cells, as above. In untreated cells, VifC133S behaved as VifS116V mutant, and was coencapsidated with Pr55Gag into VLP at levels equivalent to Vifwt (Fig. 6Bii, lane 0). In DSB-treated cell samples, VifC133S had the same phenotype as VifS116V in terms of lack of anti-DSB effect: assembly and release of VLP from Sf9 cells coexpressing Pr55Gag and VifC133S showed the same degree of DSB sensitivity as from Sf9 cells expressing Pr55Gag alone (Fig. 6Bii, and Fig. 6C).
###end p 38
###begin p 39
These results suggested that the antagonistic activity of Vif against the DSB inhibition of Gag assembly, absent from VifS116V and VifC133S mutants, was associated with the ZBD and more precisely involved residues located on the N-terminal side of loop 2. Thus, the phenotype of our Vif mutants with respect to their packaging and anti-DSB properties showed that the integrity of the ZBD structure was not required for the packaging of Vif into VLP produced by Sf9 cells, but was crucial for its DSB counteracting effect.
###end p 39
###begin title 40
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Assembly and budding pathways of HIV-1 VLP in Vif-expressing Sf9 cells
###end title 40
###begin p 41
###xml 118 121 118 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 539 541 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 574 576 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 577 579 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 580 582 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 661 663 660 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 742 744 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7b</xref>
###xml 766 769 765 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 841 843 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 844 846 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 926 928 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7c</xref>
###xml 1086 1091 1085 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7d, e</xref>
To further investigate on the mechanism of the DSB counteracting effect of Vif, Sf9 cells coexpressing Pr55Gag and Vifwt or ZBD mutants were analyzed by electron microscopy (EM) and immunoelectron microscopy (immuno-EM). Cells were infected with AcMNPV-Pr55Gag and AcMNPV-Vif, untreated or treated with DSB at 10 mug/ml at 18 h pi, harvested at 48 h pi and processed for EM or immuno-EM using anti-Vif antibody. In control Sf9 cells expressing Pr55Gag alone, the vast majority of VLP assembled at and budded from the plasma membrane (Fig. 7a), as shown in previous studies [16,64,65]. The pattern of VLP assembly and budding was drastically different in Gag+Vifwt-coexpressing cells: VLP were found in abundance in cytoplasmic vesicles (Fig. 7b). Coexpression of Vifwt did not decrease the production of VLP by Pr55Gag-expressing Sf9 cells [24,50], and vesicular VLP egressed into the extracellular medium by exocytosis (Fig. 7c). In immuno-EM, gold grains of anti-Vif antibodies were seen in close association with intravesicular VLP, or along the rim of VLP-containing vesicles (Fig. 7d, e), suggesting that Vif and Pr55Gag proteins colocalized in the same vesicular compartment.
###end p 41
###begin p 42
###xml 78 81 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink">EM and immuno-EM analysis of Pr55Gag-expressing Sf9 cells, with or without Vif<sup>wt </sup>coexpression</bold>
###xml 210 212 210 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 302 305 302 305 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 347 350 347 350 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
###xml 401 403 401 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 411 414 411 414 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c)</bold>
###xml 609 615 609 615 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d, e)</bold>
###xml 666 669 666 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 849 852 849 852 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d)</bold>
###xml 1012 1015 1012 1015 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e)</bold>
###xml 767 773 <span type="species:ncbi:9986">rabbit</span>
###xml 828 834 <span type="species:ncbi:9986">rabbit</span>
EM and immuno-EM analysis of Pr55Gag-expressing Sf9 cells, with or without Vifwt coexpression. Sf9 cells were infected with AcMNPV-Pr55Gag alone or coinfected with another baculovirus expressing Vif (AcMNPV-Vifwt) at equal MOI of each (5 PFU/cell), harvested at 48 h pi, and processed for EM analysis. (a), Control cells expressing Pr55Gag alone; (b), Sf9 coinfected with AcMNPV-Pr55Gag and AcMNPV-Vifwt. Inset (c), Enlargement of an area of the plasma membrane showing exocytosis of VLP. Note the abundance of VLP at the cell surface in (a), compared to the high VLP content of vesicular compartment in (b). (d, e), Sf9 coinfected with AcMNPV-Pr55Gag and AcMNPV-Vifwt and harvested at 48 h pi were processed for immuno-EM. Cell sections were incubated with anti-Vif rabbit antibody, followed by 5-nm colloidal gold-tagged anti-rabbit IgG antibody. (d), General view of a cell. The plasma membrane (PM) is materialized by a dotted line; the cytoplasmic area shows vesicles (VS) with intraluminal budding of VLP. (e), Enlargement of VLP-containing vesicles. Note the immunogold labelling of VLP, as well as the accumulation of gold grains at the membrane of VLP-containing vesicles.
###end p 42
###begin p 43
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 529 532 529 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 622 623 622 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 721 722 721 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 1028 1032 1028 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gag </italic>
###xml 1114 1116 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 916 921 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 943 948 <span type="species:ncbi:9606">human</span>
###xml 995 1000 <span type="species:ncbi:9606">human</span>
The proportion of VLP following the intravesicular budding and exocytosis pathway compared to the ones using the plasma membrane pathway was estimated under the EM, by counting several hundreds of VLP in subcellular compartments of more than 20 different cells. In control Sf9 cells expressing Pr55Gag alone, less than 5% VLP were found within the vesicular compartment, whereas in Gag+Vifwt-coexpressing cells, the proportion increased to 30 to 50%, viz. a 5- to 10-fold increase. Likewise, in cells coexpressing Pr55Gag and Vifwt and treated with DSB, most VLP used the intravesicular budding and exocytic pathway (Fig. 8). Interestingly, many VLP-containing vesicles showed an electron-dense, heterogenous lumen (Fig. 8), resembling multivesicular bodies (MVBs) observed in mammalian cells. MVBs belong to the late endosomal subcellular compartment, and have been identified as the preferred budding sites for WT HIV-1 particles in primary human macrophages (reviewed in [66]), as well as in human epithelial and T cells for gag mutants altered in the cluster of basic amino acids of the matrix (MAp17) domain [67].
###end p 43
###begin p 44
###xml 55 57 55 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DSB treatment of Sf9 cells coexpressing Pr55Gag and Vif<sup>wt</sup></bold>
###xml 108 110 108 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 255 258 254 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 284 287 283 286 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b)</bold>
DSB treatment of Sf9 cells coexpressing Pr55Gag and Vifwt. Sf9 coinfected with AcMNPV-Pr55Gag and AcMNPV-Vifwtat equal MOI of each (5 PFU/cell) were treated with DSB at 10 mug/ml for 30 h at 18 h pi. Cells were harvested at 48 h pi, and processed for EM. (a), General view of a cell. (b), Enlargement of a submembranal region of the cell showing VLP in the process of exocytosis. Note the abundance of VLP in the vesicular compartment in panels (a) and (b). VLP-containing vesicles reminiscent of MVBs observed in mammalian cells are indicated with arrows.
###end p 44
###begin p 45
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9</xref>
###xml 570 572 570 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 739 744 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We next examined cells coexpressing Pr55Gag and ZBD mutants of Vif under the EM, and found that, in the presence of Vif116V and VifC133S, the VLP budding pathway was similar to the one observed in Sf9 cells expressing Pr55Gag alone, i.e. a majority of VLP budding at the plasma membrane and rare intravesicular VLP (less than 10%; Fig. 9). The EM pattern of VifS116V and VifC133S mutants was consistent with their phenotype, as both mutants failed to negate the inhibitory effect of DSB on VLP assembly. Taken together, our results suggested that, in the presence of Vifwt, the VLP assembly and budding process was redirected to the vesicular compartment, and that the VLP egress via exocytosis represented a salvage pathway through which HIV-1 VLP escaped the negative effect of DSB.
###end p 45
###begin p 46
###xml 0 68 0 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink">EM analysis of Sf9 cells coexpressing Pr55Gag and ZBD mutants of Vif</bold>
###xml 131 132 131 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 154 155 154 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 433 436 433 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
EM analysis of Sf9 cells coexpressing Pr55Gag and ZBD mutants of Vif. Sf9 were coinfected with AcMNPV-Pr55Gag and AcMNPV-VifS116V (a) or AcMNPV-VifC133S (b) at equal MOI of each (5 PFU/cell), harvested at 48 h pi, and processed for EM analysis. The vast majority of VLP budding at the plasma membrane was reminiscent of Sf9 cells expressing Pr55Gag alone (refer to Fig. 7a), and contrasted with Sf9 cells coexpressing Pr55Gag and Vifwt (refer to Fig. 7b-e).
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">trans</italic>
###xml 839 840 839 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
It is generally accepted that DSB inhibits the cleavage of CAp25 into CAp24 and SP1 by the viral PR, due to its interference with the Gag substrate [8]. However, in recombinant Pr55Gag-expressing Sf9 cells, a cellular context devoid of PR and other viral proteins, DSB showed a dose-dependent inhibitory activity on VLP assembly and release [14]. The aim of the present study was to understand this dual inhibitory activity, and explain the apparent discrepancy between the DSB effects observed in mammalian and non-mammalian, insect cells. We first explored the effect of DSB on VLP production in 5BD.1 cells, a mammalian trans-packaging cell line producing VLP devoid of viral genome, as the VLP produced by AcMNPV-Pr55Gag-infected Sf9 cells. We found that DSB had only a moderate inhibitory effect on VLP yields at high DSB doses (Fig. 1), indicating that VLP assembly in 5BD.1 cells was less sensitive to DSB inhibitor, compared to Pr55Gag-expressing Sf9 cells. This suggested that the DSB negative effect on the VLP assembly process might be modulated by factors depending on the cellular or/and viral context.
###end p 48
###begin p 49
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 350 353 350 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 499 500 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 654 655 654 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 723 727 723 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6Bii</xref>
###xml 875 878 875 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6Bi</xref>
###xml 1018 1020 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 1112 1115 1112 1115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 1121 1124 1121 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6Bi</xref>
###xml 1129 1133 1129 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6Bii</xref>
###xml 1492 1494 1492 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 1550 1552 1550 1552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
We therefore investigated on the possible influence of viral components on the pattern of anti-assembly effect of DSB, and in particular the role of viral partners of Pr55Gag within the capsid. Coexpression of recombinant Pr55Gag with EnvGp160 or Vpr did not modify the level of inhibition of VLP assembly by DSB (Fig. 2), whereas coexpression of Vifwt restored the production of VLP in DSB-treated cells to levels found in the absence of the drug (Fig. 3). A panel of recombinant Vif mutants (Fig. 4) were then tested for their anti-DSB activity. We found that the DSB-antagonistic effect of Vif was retained in packaging-defective mutants of Vif (Fig. 5), but abolished by a Cys-to-Ser substitution at position 133 (Fig. 6Bii), a mutation which destroyed the zinc finger-like structure or ZBD. A phenotype similar to that of VifC133S was observed for mutant VifS116V (Fig. 6Bi), which carried a mutation on the N-terminal side of the large loop (loop 2) generated by the four HCCH coordinates with the Zn atom (Fig. 4A). Both VifC133S and VifS116V mutants were encapsidated into VLP at levels comparable to Vifwt (Fig. 6Bi and 6Bii, control lanes 0). Our results therefore suggested that (i) the anti-DSB effect and packaging into VLP were two independent functions in Vif; (ii) the function of Vif which negated the DSB-induced inhibition of VLP assembly depended on the integrity of the zinc-binding domain, and more precisely on a discrete region of loop 2 overlapping residue 116 (Fig. 4A). This region differed from the Vif packaging signals [50].
###end p 49
###begin p 50
###xml 49 52 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 180 182 180 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7b&#8211;e</xref>
###xml 360 361 360 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 640 643 640 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 770 771 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9</xref>
###xml 893 895 893 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
EM analysis of Sf9 cells coexpressing Gag and Vifwt or Vif mutants gave some insight into the cellular mechanism of anti-DSB activity of Vif. Sf9 cells coexpressing Pr55Gag and Vifwt, with or without treatment with inhibitory doses of DSB, showed a high proportion of VLP budding into intracytoplasmic vesicles and egressing via exocytosis (Fig. 7b-e and Fig. 8). This contrasted with cells expressing Pr55Gag alone, in which the majority of VLP budded at the plasma membrane (Fig. 7a). When Pr55Gag was coexpressed with one or the other of the ZBD mutants, VifS116V or VifC133S, we observed a drastic change in VLP budding, compared to Vifwt coexpression, consisting of a reversion to the plasma membrane budding pathway, as in Sf9 cells expressing Pr55Gag alone (Fig. 9). Since both ZBD mutants lacked the anti-DSB activity and failed to redirect VLP to the vesicular compartment, as did Vifwt, it might be hypothesized that the antagonistic activity of Vif towards DSB would be the indirect effect of a Vif-mediated change in the VLP assembly sites and mode of cellular exit.
###end p 50
###begin p 51
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 569 571 569 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt</sup>
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
It has been shown that the assembly and release of HIV-1 virions proceeds via two pathways, depending upon the cell type [67]: (i) in primary human macrophages, virions preferentially follow the exosomal pathway via MVBs [67-69]; (ii) in HeLa cells and T lymphocytes, the major exgress route consisted of plasma membrane addressing and direct budding at the cell surface, but MA polybasic signal mutants of Gag use the MVB pathway in these cells [67]. Sf9 cells expressing Pr55Gag alone belonged to the second category of cells [16,64,65], but when coexpressed with Vifwt, the VLP assembly and budding process mimicked the MVB budding and exocytic pathway used by MA polybasic mutants in HeLa and T cells. The hypothesis formulated above implied that the intravesicular budding and exocytic pathway of VLP would be less sensitive to DSB inhibitory activity than the plasma membrane assembly and budding pathway usually observed in insect cells. If confirmed, this would be an example of drug resistance mechanism (DSB, in the present case) which involves the bypass of a drug-sensitive assembly and budding pathway by the virus or virus-like particle progeny.
###end p 51
###begin p 52
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 462 467 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The results of our study suggested that DSB and other betulinic acid derivatives could be considered not only as antivirals for patients treatment in vivo, but also as chemical probes to analyse the molecular and cellular mechanisms of retroviral Gag assembly in vitro. In the latter context, considering Vif as a determinant of the budding pathway usage in Sf9 cells, and as a modulator of the DSB response in terms of VLP assembly, any evaluation of potential HIV-1 assembly inhibitors using the baculovirus-insect cell system should be carried out in the presence of the Vif protein.
###end p 52
###begin title 53
Methods
###end title 53
###begin title 54
Chemical synthesis of DSB
###end title 54
###begin p 55
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">O</italic>
###xml 65 67 65 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">36</sub>
###xml 68 70 68 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">56</sub>
###xml 71 72 71 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
The title compound 3-O-(3',3'-dimethylsuccinyl)-betulinic acid (C36H56O6; MW = 584.8) was obtained as originally described [5] with a few minor modifications described in our previous study [14].
###end p 55
###begin title 56
Cells
###end title 56
###begin p 57
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 373 395 371 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Spodoptera frugiperda </italic>
###xml 573 575 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 576 578 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 579 581 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 582 584 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 169 174 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 278 284 <span type="species:ncbi:9913">bovine</span>
###xml 285 289 <span type="species:ncbi:9913">calf</span>
###xml 373 394 <span type="species:ncbi:7108">Spodoptera frugiperda</span>
Simian 5BD.1 packaging cells (obtained from D. Rekosh and M.-L. Hammarskjold, University of Virginia at Charlottesville) were CMT3-COS-derived cells that stably express HIV-1 Gag-Pol and Env proteins but no Nef [29,30]. They were maintained in Iscove's medium supplemented with bovine calf serum (10%), hygromycin (200 mug/ml), gentamycin (50 mug/ml) and G418 (1.5 mg/ml). Spodoptera frugiperda Sf9 cells were maintained as monolayers, and infected with recombinant baculovirus at a multiplicity of infection (MOI) ranging from 2.5 to 20 PFU/cell, as previously described [16,65,70,71].
###end p 57
###begin title 58
Recombinant baculoviruses
###end title 58
###begin p 59
###xml 68 71 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vpr</italic>
###xml 106 129 106 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Autographa californica </italic>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 252 259 252 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(i) Gag</italic>
###xml 252 259 252 259 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>(i) Gag</italic></bold>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 416 448 416 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(ii) Envelope glycoprotein Gp160</italic>
###xml 416 448 416 448 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>(ii) Envelope glycoprotein Gp160</italic></bold>
###xml 516 525 516 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(iii) Vpr</italic>
###xml 516 525 516 525 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>(iii) Vpr</italic></bold>
###xml 641 643 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 646 662 646 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(iv) Vif clones </italic>
###xml 646 662 646 662 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>(iv) Vif clones </italic></bold>
###xml 677 678 677 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 691 694 691 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">wt </sup>
###xml 746 749 746 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 788 791 788 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 939 942 939 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 957 960 957 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 966 969 966 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 1095 1098 1095 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 1123 1126 1119 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 1219 1222 1215 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 1228 1231 1224 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 1237 1240 1233 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 1258 1261 1254 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sub</italic>
###xml 1316 1318 1308 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1319 1321 1311 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 18 23 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 319 324 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
All the different HIV-1 genes used in the present study, except for vpr, were inserted into the genome of Autographa californica MultiCapsid NucleoPolyhedrosis Virus (AcMNPV) under the control of a chimeric AcMNPV-GmNPV polyhedrin promoter [16,65,70]. (i) Gag. AcMNPV-Pr55Gag, expressing the full-length wild type (WT) HIV-1 Gag polyprotein (Pr55Gag), has been described in detail in previous studies [14,16,65,71]. (ii) Envelope glycoprotein Gp160. AcMNPV-Gp160 expressed the CCR5-tropic YU2 envelope glycoprotein. (iii) Vpr. The baculovirus clone expressing the oligohistidine-tagged Vpr protein (AcMNPV-Vpr) was obtained from Eric Cohen [72]. (iv) Vif clones (refer to Fig. 4). AcMNPV-Vifwt expressed the full-length wild type Vif protein. VifsubA (EKEWH-to-DINQN substitution) and VifsubB (WRxxxY-to-FExxxF substitution) were mutated in two tryptophan-containing motifs, at position 76-80 and 89-94, respectively; the double mutant VifsubC carried both subA and subB mutations; mutant VifKRA8 had 8 basic residues in the C-terminal domain (residues 156-192) replaced by alanine residues. VifsubCDelta170 carried the VifsubC multiple substitutions and an additional deletion of the 23 C-terminal residues of Vif. VifsubA, VifsubB, VifsubC, VifKRA8 and VifsubCDelta170 have been characterized in previous studies [49,50]. Substitutions Ser-to-Val at position 116 and Cys-to-Ser at position 133 in the Vif sequence were constructed using the conventional PCR-SOE technique. Recombinant Vif mutants VifS116V and VifC133S were generated by recombination with the baculoviral genome. All mutants were verified by DNA sequencing.
###end p 59
###begin title 60
Gag assembly assays
###end title 60
###begin p 61
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
Aliquots of Sf9 cells (106) were infected with recombinant AcMNPV at MOI 10. At 18 h postinfection (pi), increasing quantities of DSB in DMSO were added. To avoid possible interference with DMSO effect, DMSO was kept constant in volume in the different samples. A stock solution of DSB (10 mg/ml DMSO) was diluted with DMSO to obtain a range of DSB concentrations from 0.5 to 30 mug DSB per 3 mul-aliquot of DMSO, and each 3 mul-aliquot was added to 1 ml of culture medium overlaying the cell monolayers. The cells were harvested at 48 h pi, and extracellular VLP quantitatively assayed in the culture medium.
###end p 61
###begin title 62
Isolation of extracellular virus-like particles (VLP)
###end title 62
###begin p 63
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 250 251 250 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 394 395 394 395 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 509 510 509 510 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 623 624 623 624 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Sf9 cell culture supernatants were clarified by low-speed centrifugation, then VLP recovered using sucrose-step gradient centrifugation[73], by pelleting through a cushion of 20% sucrose in TNE buffer (TNE: 100 mM NaCl, 10 mM Tris-HCl pH 7.4, 1 mM Na2EDTA). The pellets were gently resuspended in PBS (0.20-0.25 ml), and VLP further purified by isopycnic ultracentrifugation in linear sucrose-D2O gradients [50]. Gradients (10-ml total volume, 30-50%, w:v) were generated from a 50% sucrose solution made in D2O buffered to pH 7.2 with NaOH, and a 30% sucrose solution made in 10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 5.7 mM Na2EDTA. The gradients were centrifuged for 18 h at 28 krpm in a Beckman SW41 rotor. Aliquots of 0.5 ml were collected from the top, and proteins analyzed by SDS-PAGE, immunoblot analysis with or without autoradiography.
###end p 63
###begin title 64
Gel electrophoresis and membrane transfer
###end title 64
###begin p 65
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 524 530 <span type="species:ncbi:9986">rabbit</span>
###xml 532 537 <span type="species:ncbi:10090">mouse</span>
###xml 541 545 <span type="species:ncbi:9925">goat</span>
Polyacrylamide gel electrophoresis of SDS-denatured protein samples (SDS-PAGE), and immunoblotting analysis have been described in detail in previous studies [70,71,74]. Briefly, proteins were electrophoresed in SDS-denaturing, 12%-polyacrylamide gel and electrically transferred to nitrocellulose membrane (Hybondtrade mark-C-extra; GE Healthcare Bio-Sciences). Blots were blocked in 5% skimmed milk in Tris-buffered saline (TBS) containing 0.05% Tween-20 (TBS-T), rinsed in TBS-T, then successively incubated with primary rabbit, mouse or goat anti-Gag antibodies, and relevant anti-IgG secondary antibodies, at working dilutions ranging from 1:5,000 to 1:40,000. Apparent molecular weights were estimated by comparison with prestained protein markers (PageRulertrade mark prestained protein ladder; Fermentas Inc., Hanover, MD).
###end p 65
###begin title 66
Antibodies and immunological analysis
###end title 66
###begin p 67
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pst </italic>
###xml 278 281 278 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gag</italic>
###xml 281 285 281 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Lai </sub>
###xml 926 928 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 1224 1226 1223 1225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1349 1351 1347 1349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1745 1747 1734 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1748 1750 1737 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 5 10 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 73 79 <span type="species:ncbi:9986">rabbit</span>
###xml 296 301 <span type="species:ncbi:10090">Mouse</span>
###xml 554 559 <span type="species:ncbi:10090">Mouse</span>
###xml 687 693 <span type="species:ncbi:9986">rabbit</span>
###xml 958 964 <span type="species:ncbi:9986">rabbit</span>
###xml 974 979 <span type="species:ncbi:10090">mouse</span>
###xml 1041 1052 <span type="species:ncbi:3704">horseradish</span>
###xml 1244 1250 <span type="species:ncbi:9986">rabbit</span>
###xml 1259 1264 <span type="species:ncbi:10090">mouse</span>
Anti-HIV-1 Gag polyclonal antibody (laboratory-made; [50]) was raised in rabbit by injection of bacterially-expressed, GST-fused and affinity-purified C-truncated Gag protein consisting of full-length MA domain and the first seventy-eight residues of the CA domain (Pst I site; gagLai sequence). Mouse monoclonal antibody (mAb) anti-CAp24 (Epiclone #5001) and mAb anti-MAp17 (Epiclone #5003) were obtained from Cylex Inc. (Columbia, MD). MAb 41A9, directed against the Gp41 domain of the EnvGp160, was obtained from Hybridolab (Institut Pasteur, Paris). Mouse anti-Hisx6-tag antibody (Tag-100 antibody) was purchased from Qiagen SA (Courtabaeuf, France). Anti-Vif antibody was raised in rabbit by injection of bacterially-expressed His-tagged Vif protein purified by guanidine denaturation and progressive renaturation of insoluble protein inclusion, followed by affinity chromatography on Ni-column (a gift from E. Decroly; [75]). Phosphatase-labelled anti-rabbit, or anti-mouse IgG conjugates were purchased from Sigma (St Louis, MO), and horseradish peroxidase-labelled conjugates from Sigma (St Louis, MO). For immunological quantification of membrane-transferred Gag and Vif proteins, blots were reacted with secondary 35SLR-labelled anti-rabbit or anti-mouse whole IgG antibody (GE Healthcare Bio-Sciences; 2,000 Ci/mmol; 20-30 muCi per 100 cm2 membrane), and exposed to radiographic films (Hyperfilmtrade mark MP, GE Healthcare Bio-Sciences). Autoradiograms were scanned and quantitated by densitometric analysis, using the VersaDoc image analyzer and the Quantity One program (BioRad). Alternatively, protein bands were excised from blots and radioactivity measured in a scintillation counter (Beckman LS-6500), as previously described [14,50].
###end p 67
###begin title 68
Electron microscopy (EM) and immunoelectron microscopy (immuno-EM)
###end title 68
###begin p 69
###xml 175 176 175 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 226 227 226 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 472 473 472 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 939 940 933 934 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 943 945 937 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 946 948 940 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 949 951 943 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 952 954 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 746 752 <span type="species:ncbi:9986">rabbit</span>
###xml 757 761 <span type="species:ncbi:9925">goat</span>
Baculovirus-infected Sf9 cells were harvested at 48 h pi, pelleted, fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.5, post-fixed with osmium tetroxide (2% in H2O) and treated with 0.5% tannic acid solution in H2O. The specimens were dehydrated and embedded in Epon (Epon-812; Fulham, Latham, NY). Ultrathin sections were stained with 2.6% alkaline lead citrate and 0.5% uranyl acetate in 50% ethanol, and post-stained with 0.5% uranyl acetate solution in H2O [64]. For immuno-EM analyses, cell specimens were included in metacrylate resin (Lowicryl K4M). Sections on grids were reacted with polyclonal anti-Vif antibody (diluted at 1:100 in Tris-buffered saline) overnight at 4degreesC. Reaction with by 5-nm gold-conjugated anti-rabbit IgG goat antibody (EM-GAR5; British Biocell International, Cardiff, UK) was carried out at room temperature for 1 h, and sections post-stained with 0.5% 0.5% uranyl acetate solution in H2O [50,64,74,76]. Grids were examined under a Jeol JEM-1400 electron microscope, equiped with an ORIUStrade mark digitalized camera (Gatan France, 78113-Grandchamp). For statistical EM analyses, a minimum of 30 grid squares containing 10 to 20 cell sections each were examined for counting VLP budding at the cell surface, or for core-like particles assembled intracellularly.
###end p 69
###begin title 70
Competing interests
###end title 70
###begin p 71
The authors declare that they have no competing interests.
###end p 71
###begin title 72
Authors' contributions
###end title 72
###begin p 73
SDF performed the bench work, and BG and PB performed the EM analyses. PC synthesized the DSB. SSH and PB conceived the strategies and designed the experiments. SB contributed to data analysis. PB wrote the manuscript. All the authors read and approved the final manuscript.
###end p 73
###begin title 74
Acknowledgements
###end title 74
###begin p 75
This work has been supported by the Agence Nationale de Recherche sur le SIDA (ANRS Grant 2005-2006/003 and DendrAde-2007). SDF was the recipient of an ANRS fellowship. We are grateful to Eric Cohen (University of Montreal, Quebec) for supplying us with the baculoviral clone expressing His-tagged Vpr, and to David Rekosh and Mari-Lou Hammarskjold (University of Virginia at Charlottesville) for their gift of 5BD.1 packaging cells. We acknowledge with thank Elisabeth Errazuriz (Centre Commun d'Imagerie de Laennec) for her significant contribution to specimen processing and EM studies, and Sylvie Fiorini for her expert technical assistance. The efficient secretarial aid of Cathy Berthet is also gratefully acknowledged.
###end p 75
###begin article-title 76
###xml 5 33 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation
###end article-title 76
###begin article-title 77
###xml 17 20 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing
###end article-title 77
###begin article-title 78
###xml 32 37 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Determinants of activity of the HIV-1 maturation inhibitor PA-457
###end article-title 78
###begin article-title 79
###xml 81 86 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 91 94 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid
###end article-title 79
###begin article-title 80
###xml 68 71 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents
###end article-title 80
###begin article-title 81
###xml 29 64 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation
###end article-title 81
###begin article-title 82
###xml 80 115 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids
###end article-title 82
###begin article-title 83
###xml 30 35 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Betulinic acid derivatives as HIV-1 antivirals
###end article-title 83
###begin article-title 84
###xml 17 52 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions
###end article-title 84
###begin article-title 85
###xml 76 111 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation
###end article-title 85
###begin article-title 86
###xml 27 62 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat)
###end article-title 86
###begin article-title 87
###xml 70 105 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro
###end article-title 87
###begin article-title 88
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 91 96 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles
###end article-title 88
###begin article-title 89
###xml 117 122 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells
###end article-title 89
###begin article-title 90
###xml 76 79 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
3-O-glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents
###end article-title 90
###begin article-title 91
###xml 40 75 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells
###end article-title 91
###begin article-title 92
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564
###end article-title 92
###begin article-title 93
###xml 30 65 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41
###end article-title 93
###begin article-title 94
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 assembly, release and maturation
###end article-title 94
###begin article-title 95
###xml 80 115 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly
###end article-title 95
###begin article-title 96
###xml 26 61 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor
###end article-title 96
###begin article-title 97
###xml 49 84 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag)
###end article-title 97
###begin article-title 98
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than Gag and is phosphorylated in infected cells
###end article-title 98
###begin article-title 99
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 60 63 <span type="species:ncbi:103820">Gag</span>
###xml 68 71 <span type="species:ncbi:103820">Gag</span>
Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing
###end article-title 99
###begin article-title 100
###xml 25 53 <span type="species:ncbi:12721">human immunodeficiency virus</span>
High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site
###end article-title 100
###begin article-title 101
###xml 31 36 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation
###end article-title 101
###begin article-title 102
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif
###end article-title 102
###begin article-title 103
###xml 54 59 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Characterization of a novel Cullin5 binding domain in HIV-1 Vif
###end article-title 103
###begin article-title 104
###xml 70 105 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines
###end article-title 104
###begin article-title 105
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase infectivity
###end article-title 105
###begin article-title 106
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Assembling the human immunodeficiency virus type 1
###end article-title 106
###begin article-title 107
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Gag proteins: diverse functions in the virus life cycle
###end article-title 107
###begin article-title 108
Retrovirus budding
###end article-title 108
###begin article-title 109
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions
###end article-title 109
###begin article-title 110
###xml 20 25 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cell biology of HIV-1 and other retroviruses
###end article-title 110
###begin article-title 111
###xml 44 79 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail
###end article-title 111
###begin article-title 112
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis
###end article-title 112
###begin article-title 113
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of Nef with the subviral ribonucleoprotein complex
###end article-title 113
###begin article-title 114
###xml 24 59 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity
###end article-title 114
###begin article-title 115
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase
###end article-title 115
###begin article-title 116
###xml 71 106 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation
###end article-title 116
###begin article-title 117
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
NMR structure of the HIV-1 regulatory protein Vpr
###end article-title 117
###begin article-title 118
###xml 89 124 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr
###end article-title 118
###begin article-title 119
###xml 22 57 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation
###end article-title 119
###begin article-title 120
###xml 101 136 <span type="species:ncbi:11723">simian immunodeficiency viruses SIV</span>
###xml 146 149 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm)
###end article-title 120
###begin article-title 121
###xml 91 126 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
A leucine triplet repeat sequence (LXX)4 in p6 gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles
###end article-title 121
###begin article-title 122
Interaction with the p6 domain of the Gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses
###end article-title 122
###begin article-title 123
###xml 14 49 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 202 207 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 211 216 <span type="species:ncbi:9606">human</span>
Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo
###end article-title 123
###begin article-title 124
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vif protein binds to the Pr55GAG precursor
###end article-title 124
###begin article-title 125
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Interaction and co-encapsidation of HIV-1 Vif and Gag recombinant proteins
###end article-title 125
###begin article-title 126
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production
###end article-title 126
###begin article-title 127
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vif-mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity
###end article-title 127
###begin article-title 128
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription
###end article-title 128
###begin article-title 129
###xml 23 58 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains
###end article-title 129
###begin article-title 130
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity
###end article-title 130
###begin article-title 131
###xml 57 92 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 vif protein
###end article-title 131
###begin article-title 132
###xml 19 24 <span type="species:ncbi:9606">human</span>
The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures
###end article-title 132
###begin article-title 133
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation
###end article-title 133
###begin article-title 134
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway
###end article-title 134
###begin article-title 135
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identification of an APOBEC3G binding site in HIV-1 Vif and inhibitors of Vif-APOBEC3G binding
###end article-title 135
###begin article-title 136
###xml 66 69 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 81 84 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
Comparison of Vif sequences from diverse geographical isolates of HIV type 1 and SIV(cpz) identifies substitutions common to subtype C isolates and extensive variation in a proposed nuclear transport inhibition signal
###end article-title 136
###begin article-title 137
###xml 40 75 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity
###end article-title 137
###begin article-title 138
###xml 27 62 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Mutational analysis of the human immunodeficiency virus type 1 Vif protein
###end article-title 138
###begin article-title 139
###xml 30 35 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Morphopoietic determinants of HIV-1 GAG particles assembled in baculovirus-infected cells
###end article-title 139
###begin article-title 140
###xml 28 31 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gag</italic>
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Functional domains of HIV-1 gag-polyprotein expressed in baculovirus-infected cells
###end article-title 140
###begin article-title 141
###xml 29 34 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Intracellular trafficking of HIV-1 Gag: how Gag interacts with cell membranes and makes viral particles
###end article-title 141
###begin article-title 142
###xml 33 68 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body
###end article-title 142
###begin article-title 143
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 egress is gated through late endosomal membranes
###end article-title 143
###begin article-title 144
Visualization of retroviral replication in living cells reveals budding into multivesicuar bodies
###end article-title 144
###begin article-title 145
###xml 75 110 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Sequence requirement for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles
###end article-title 145
###begin article-title 146
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells
###end article-title 146
###begin article-title 147
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 73 97 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Analysis of HIV-1 Vpr determinants responsible for cell growth arrest in Saccharomyces cerevisiae
###end article-title 147
###begin article-title 148
RNA is a structural element in retrovirus particles
###end article-title 148
###begin article-title 149
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">eed </italic>
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 47 53 <span type="species:ncbi:10090">murine</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
H-EED, the product of the human homolog of the murine eed gene, binds to the matrix protein of HIV-1
###end article-title 149
###begin article-title 150
###xml 110 115 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into vif-defective HIV-1 particles
###end article-title 150
###begin article-title 151
###xml 4 9 <span type="species:ncbi:9606">Human</span>
###xml 69 74 <span type="species:ncbi:9606">Human</span>
The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1
###end article-title 151

